Varenicline OTC Trial on Efficacy and Safety

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

313 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-07

Study Completion Date

2022-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

NCT00143299

Smoking Cessation

COMPLETED PHASE3

Varenicline (Chantix™) for the Treatment of Alcohol Dependence

NCT00705523

Alcoholism

COMPLETED PHASE2

Relapse Prevention With Varenicline

NCT00944554

Recurrence Smoking Cessation Substance-Related Disorders

COMPLETED PHASE4

Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation

NCT02575183

Nicotine Dependence

COMPLETED PHASE4

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

NCT00594204

Smoking Cessation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Given the recent research on varenicline showing that it is more effective than nicotine patch and bupropion, and with the removal of the box warning, research is needed to assess whether smokers can use varenicline without a prescription and formal behavioral support. To test this, the primary goal of the proposed research is to test whether varenicline is a candidate for switching from prescription (Rx) to OTC, and whether a dose lower than that currently approved is as effective in an OTC environment. To understand the within-person mechanisms explaining how and when OTC varenicline might improve cessation outcomes, the investigators also propose to assess experience with OTC varenicline via (a) ecological momentary assessment (EMA).

Primary Objectives:

1. To assess the safety and effectiveness of the current FDA-approved 1 mg b.i.d. varenicline for smoking cessation in comparison with placebo when used in a simulated OTC study condition.
2. To assess the safety and effectiveness of .5mg b.i.d. varenicline in comparison with 1mg b.i.d. varenicline and placebo when used in a simulated OTC study condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Dependence Withdrawal Symptoms Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.0mg varenicline b.i.d.

Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.

Group Type EXPERIMENTAL

1.0mg Varenicline b.i.d.

Intervention Type DRUG

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

0.5mg varenicline b.i.d.

Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study

Group Type EXPERIMENTAL

0.5mg Varenicline b.i.d.

Intervention Type DRUG

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

0.0mg placebo varenicline b.i.d.

Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.

Group Type PLACEBO_COMPARATOR

0.0mg placebo Varenicline b.i.d.

Intervention Type DRUG

Product that looks like active varenicline, but contains no active ingredient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1.0mg Varenicline b.i.d.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Intervention Type DRUG

0.5mg Varenicline b.i.d.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Intervention Type DRUG

0.0mg placebo Varenicline b.i.d.

Product that looks like active varenicline, but contains no active ingredient

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 21 years of age or older
2. Self-reported daily smoker
3. Breath CO \> 10ppm
4. Motivated to quit smoking completely within five weeks of the Screening Visit (\>5 on reported motivation)
5. Capable of and agree to complete study requirements
6. Literate in English, self-report
7. Must be available for the duration of study
8. Informed consent obtained
9. Willing and able to provide additional data between visits using ecological momentary assessment (EMA)
10. Must own study compatible smart-phone (iPhone or Android)

1. 21 years of age or older
2. Self-reported daily smoker
3. Positive cotinine from urine sample
4. Motivated to quit smoking completely within five weeks of the Screening Visit (\>5 on reported motivation)
5. Capable of and agree to complete study requirements
6. Literate in English, self-report
7. Must be available for the duration of study
8. Informed consent obtained

10\. Must own study compatible smart-phone (iPhone or Android) 11. Must be a current resident of the United States

Exclusion Criteria

1. Any self-report, diagnosis or treatment of heart attack, unstable angina, angioedema, seizures, cerebrovascular accident (CVA) within the last six months.
2. Any self-report, diagnosis or treatment of bipolar, schizophrenia or suicidal ideation within the last six months. (For suicidal ideation a score of ≥7 on the Suicidal Behavior Questionnaire, see Appendix 15)
3. Self-report of diagnosis or treatment for depression within the past six months, unless participant has written permission by their healthcare provider to participate
4. Systolic blood pressure 160 or higher and/or diastolic blood pressure 100 or higher (see site applicable SOP for Evaluating and Reporting Blood Pressure and Appendices 5 and 6 for participant handouts)
5. History of renal disease
6. Allergy to any of the ingredients in varenicline
7. Participation in another smoking cessation program or any type of clinical trial in the past 3 months
8. Use of any smoking cessation medication in the past three months
9. Any other medical condition(s) which the licensed study physician deems unacceptable for participation in this study
10. Positive drug screen indicating possible substance abuse (eg opiates, amphetamines, benzodiazepines, cocaine or other substances), unless participant can show that the medication has been prescribed by licensed clinical provider.
11. Consume greater than 21 alcohol drinks per week.
12. No two members of the same household may participate in this study
13. No study staff or their immediate family may participate in the study
14. Females who are pregnant, breast feeding, or not currently using a medically approved form of birth control and unwilling to do so.

Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, and condoms.

1. Any self-report, diagnosis or treatment of heart attack, unstable angina, angioedema, seizures, cerebrovascular accident (CVA) within the last six months.
2. Any self-report, diagnosis or treatment of bipolar, schizophrenia or suicidal ideation within the last six months. (For suicidal ideation a score of ≥7 on the Suicidal Behavior Questionnaire, see Appendix 15)
3. Self-report of diagnosis or treatment for depression within the past six months, unless participant has written permission by their healthcare provider to participate
4. History of renal disease
5. Allergy to any of the ingredients in varenicline
6. Participation in another smoking cessation program or any type of clinical trial in the past 3 months
7. Use of any smoking cessation medication in the past three months
8. Any other medical condition(s) which the licensed study physician deems unacceptable for participation in this study
9. Consume greater than 21 alcohol drinks per week.
10. No two members of the same household may participate in this study
11. No study staff or their immediate family may participate in the study
12. Females who are pregnant, breast feeding, or not currently using a medically approved form of birth control and unwilling to do so.

Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, and condoms.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes